Brian O’Callaghan Is the Chief Executive Officer and board member of Deep Genomics. 

With over 30 years experience as a senior life science executive, Brian brings extensive knowledge within the biotech, big pharma and clinical research organization (CRO) sectors. Previously, he held CEO positions at ObsEva SA, Petra Pharma, Acucela, Sangart and BioPartners.  Earlier in his career, Brian held multiple senior management positions at Pfizer, Merck Serono, Novartis, Covance and NPS Pharmaceuticals. 

Brian received a Marketing Diploma from the Marketing Institute of Ireland and a Master of Business Administration (MBA) from the Henley Business School at the University of Reading.

Brendan Frey is an internationally acclaimed entrepreneur, engineer and scientist. He is Chief Innovation Officer, Founder and board member of Deep Genomics and co-founder of the Vector Institute for Artificial Intelligence. Brendan made fundamental contributions in the fields of deep learning, genomic medicine, and information technology. He co-authored over 200 papers in these areas, including over a dozen that appeared in Nature, Science and Cell and were on multiple occasions highlighted on the front covers of those magazines. His work with Geoffrey Hinton on the 'wake-sleep algorithm' helped to launch the field of deep learning (Science 1995). His work on deep learning and on factor graphs forms the foundation of thousands of products used world-wide; for example, the WiFi telecommunications standard is based on an algorithm that Brendan co-invented.

Brendan was a pioneer in developing AI systems that could accurately predict normal and pathological cell and genome biology, facilitating biomedical breakthroughs. This work led to the discovery of new biology, the founding of Deep Genomics in 2015, the first AI system for predicting pathogenic mutations and identifying therapeutic targets, and the development of new therapeutic candidates for patients with genetic disorders. 

Brendan is Professor of Engineering and Medicine at the University of Toronto and is a Fellow of the American Association for the Advancement of Science, a Fellow of the Institute of Electrical and Electronic Engineers, a Senior Fellow of the Canadian Institute for Advanced Research, and a Fellow of the Royal Society of Canada. Brendan has advised the leadership of Microsoft Research on machine learning and deep learning technology, and he was a member of its Technical Advisory Board. He has held numerous researcher and professor positions at the University of Illinois at Urbana-Champaign, Cambridge University in England, the Isaac Newton Institute for Mathematical Sciences and the University of Waterloo.

Brendan received his Ph.D. from the University of Toronto in 1997.

David B. Johnston, Chief Financial Officer. Dave brings over thirty years of senior financial leadership experience. Currently, he is principal of dbjconsulting llc, providing financial and strategic advice to emerging life science companies. Most recently he was Chief Financial Officer for ImmunoGen, Inc. an oncology focused biotech based in Waltham, MA. During his tenure at ImmunoGen he led several public offerings as well as a creative, non-dilutive royalty financing.

Prior to ImmunoGen, Dave served as CFO for Aveo Oncology and Genzyme Biosurgery where he led both of their initial public offerings as well as leading several strategic initiatives, both on the buy side as well as the sell side.

Mr. Johnston earned a B.S. at Washington and Lee University and an MBA at the University of Michigan. Mr. Johnston sat on the board of directors of RAW Art Works, a nonprofit youth arts organization, as well as Tissue Banks International, one of the largest eye and tissue bank non-profits in the United States.

Clive Bertram is the Chief Business Officer at Deep Genomics. He comes with over 30 years of experience in commercialization, strategic, corporate and business development in the pharmaceutical industry. Most recently, he served as CCO at ObsEva, Petra Pharma and Sangart. Prior to his CCO roles, Clive held multiple senior management positions at Pharmion Limited, Chiron Biopharmaceuticals, Celltech and Eli Lilly. Clive has also served as an independent consultant leading client thinking for strategic and marketing planning and business development.

He holds a BSc (Hons.) in Pharmacology and Chemistry from the University of Sheffield

Tom Masterson is the Chief Operating Officer at Deep Genomics. Holding responsibility for the Project Management Office and executive function, Tom brings structure and continuity to the company, ensuring that corporate goals are supported by the work of our employees. 

Prior to Deep Genomics, Tom spent time in medical devices, contract research, and healthcare design strategy, before launching his own startup, Caregiver Support Technologies. The company's digital Assistant, Blue, was designed to help family caregivers and self managed patients get physical and financial support from their communities.

Tom received his B.Sc. from the University of British Columbia, where he focused on Cell Biology and Genetics. He later received his M.B.A. at Harvard Business School. He represented both schools in rugby, serving as club president at Harvard.

Greg Hoffman is the Chief Scientific Officer at Deep Genomics, leading the team responsible for generating rich data sets to train and validate our AI platform by applying state of the art capabilities in cell biology, molecular biology, robotics, screening, and animal models.  Greg and his team play a key strategic role collaborating with our internal machine learning team and external partners to identify novel applications of our AI platform to address key unmet needs in target discovery and therapeutics development for RNA-biology.

Greg brings over 20 years of experience in the biotechnology and pharmaceutical sector, including leadership roles at Arbor Biotechnology, Obsidian Therapeutics, Sana Biotechnology, and Novartis.  Greg is an experienced leader in building innovative technology platforms to uncover mechanisms of human disease and develop novel therapeutics, working at the interface of biology and computational methods in multiple disciplines including structural biology, functional genomics, gene editing, and development of cell and gene therapies.

Greg earned his BA in Biochemistry and PhD Biophysics at Cornell and completed his postdoctoral studies at Harvard Medical School where he was a Helen Hay Whitney Fellow and a LAM Foundation Fellow. 

Radu Dobrin serves as the Chief Technology Officer at Deep Genomics, where he spearheads the integration of artificial intelligence and machine learning. He believes that a prediction is only as good as the data it follows and is passionate about linking analytical predictions to biological validation. At Deep Genomics, he leads the team in the development of AI foundation models to fundamentally change the drug development process.

Radu earned his Ph.D. in Physics of Disordered Media from Michigan State University in 2002. During his doctoral studies, he conducted independent research in various subfields of theoretical solid-state physics, solving complex problems by designing algorithmic methods and deriving analytical solutions.

Jing serves as the Vice President of Strategy and Business Development at Deep Genomics, where she brings a profound commercial perspective to the organization. With a focus on new product planning, portfolio strategy, and business development, Jing plays a crucial role in shaping the company's strategic direction.

Before her tenure at Deep Genomics, Jing held roles as a project and team leader at Guidehouse Inc. (formerly Navigant Consulting), dedicated to offering strategic advisory and management consulting services to pharmaceutical and biotech entities. Her responsibilities encompassed guiding new product launches, franchise and brand strategy, business development, and market research initiatives.

Jing is a Siebel Scholar and holds a Ph.D. in Biological Engineering from Massachusetts Institute of Technology. During her graduate studies, she developed and commercialized a novel bioengineering device for genomic damage research. Prior to MIT, Jing earned a B.A.Sc) in Engineering Science, with a major in Biomedical Engineering at the University of Toronto, Canada.

Asha Rostamianfar is the Head of Engineering at Deep Genomics. He and his team have the mission to engineer software around genome biology to accelerate data-centric, AI-driven drug discovery and development processes.

Prior to Deep Genomics, he worked at Color Health, where he was the technical lead of the bioinformatics team. At Color, he primarily focused on building the large-scale computational infrastructure to process all of Color’s genomic data as well as supporting large-scale initiatives like the NIH All of Us Research Program. Prior to that, he worked at Google for more than 7 years and was one of the founding members of the Google Cloud Healthcare & Life Sciences initiative. He led a team of engineers to build software solutions to analyze genomic data at scale on the Google Cloud Platform (GCP). He also led a team of engineers to develop novel solutions for combating malware in Google’s advertising network via both machine learning models and efficient manual review tools.

Asha received a bachelor’s degree in Software Engineering from the University of Waterloo, and a master’s degree in Computational Biology from the University of Toronto.

Tehmina Masud is the Vice President and Head of Target Identification at Deep Genomics. Tehmina leads a team of multidisciplinary biologists and geneticists, driving innovative target identification and discovery platforms leveraging Deep Genomics’ AI/ML models and advanced statistical genetic techniques.

With over 14 years of medical and research experience, Tehmina brings extensive expertise in genetics, translational research, and precision medicine across diverse therapeutic areas. Between 2013 and 2019, Tehmina served as a postdoctoral fellow at the BC Cancer Research Center in Vancouver, Canada. During that time, Tehmina made significant contributions to cross-functional oncology research, focusing on DNA repair pathways, tumor evolution, targeted therapies, and cutting-edge single-cell genomic technologies.  

Tehmina holds a Ph.D. in Human Genetics from the University of Michigan and an MBBS from Pakistan.

Steven F. Dowdy, chair of the Scientific Advisory Board at Deep Genomics, specializes in the development of RNA therapeutics and in oligonucleotide delivery systems. He serves as a Professor of Cellular & Molecular Medicine at University of California at San Diego School of Medicine His lab is focused on the molecular details of delivery of RNA therapeutics across the endosomal lipid bilayer and the synthesis of endosomal escape domains to overcome this rate-limiting billion year old barrier, and was the first to synthesize bioreversible, charge neutralizing phosphotriester backbone RNAi prodrug triggers that avoids kidney clearance, increases metabolic stability and enhances endosomal escape. 

Previously, Steven was a Howard Hughes Medical Institute Investigator for 18 years (1994-2012) and an Assistant Professor at Washington University School of Medicine, St. Louis (1994-2001). He first started advising biotech and pharmaceutical companies when he was a graduate student and currently sits on five SABs.  Steven is a thrice-elected member of the Board of Directors of the Oligonucleotide Therapeutics Society (OTS). 

He received his Ph.D. in Molecular Genetics from UC Irvine working on tumor suppressor genes, and performed his postdoctoral fellowship at MIT working on the biochemistry of the Rb tumor suppressor gene.

Mark Edbrooke, Ph. D., has oligonucleotide experience spanning over two decades at AstraZeneca, GlaxoSmithKline and as an independent consultant. After earning his PhD in molecular biology from the University of London, he ran a transnational gene interference department at GSK that generated target identification and validation data for all therapeutic areas across the company. He founded and led the Discovery Performance Unit (DPU) within GSK focused on the development of therapeutic siRNAs and on therapeutic antisense oligonucleotides. He then joined AstraZeneca, where he worked on alliances with Ionis Pharmaceuticals, Regulus Therapeutics and Moderna Therapeutics.

Masad Damha, an advisor at Deep Genomics, is a Distinguished James McGill Professor of Chemistry with over 35 years of experience in nucleic acid drug discovery and development.  His research group at McGill University focuses on synthesis and structural analyses of chemically modified oligonucleotides directed toward biomedical and diagnostic applications. 

His 200+ publications and dozens of patents issued have been widely cited and used in both fundamental sciences and oligonucleotide based therapeutic applications. Masad is the recipient of several awards from the Canadian Society for Chemistry, the Queen Elizabeth II Diamond Jubilee Medal (Governor General of Canada), and McGill’s Fessenden Professorship in Science Innovation. He has recently served as President of the International Society of Nucleosides, Nucleotides, Nucleic Acids, and of the Oligonucleotide Therapeutics Society.    

Masad graduated from McGill with a B.Sc. (Hons) in Chemistry (1983) and then a Ph.D. in Organic Chemistry (1988) under the mentorship of Kelvin K. Ogilvie developing methods for the chemical synthesis of RNA and its analogues. 

Yann LeCun is VP & Chief AI Scientist at Facebook and Silver Professor at NYU affiliated with the Courant Institute of Mathematical Sciences & the Center for Data Science. He was the founding Director of Facebook AI Research and of the NYU Center for Data Science. He received an Engineering Diploma from ESIEE (Paris) and a PhD from Sorbonne Université. After a postdoc in Toronto he joined AT&T Bell Labs in 1988, and AT&T Labs in 1996 as Head of Image Processing Research. He joined NYU as a professor in 2003 and Facebook in 2013. His interests include AI machine learning, computer perception, robotics and computational neuroscience. He is the recipient of the 2018 ACM Turing Award (with Geoffrey Hinton and Yoshua Bengio) for "conceptual and engineering breakthroughs that have made deep neural networks a critical component of computing", a member of the National Academy of Engineering and a Chevalier de la Légion d’Honneur.

Benjamin Neale is an associate professor in the Analytic and Translational Genetics Unit (ATGU) at Massachusetts General Hospital (MGH), where he directs the Genomics of Public Health Initiative. He is also an associate professor in medicine at Harvard Medical School, and an institute member at the Broad Institute. He co-leads the ADHD Initiative, a collaborative effort that focuses on genomic studies with the Broad Institute, is an active member of the Psychiatric Genomics Consortium (PGC) steering committee and analysis committee, and currently co-chair of the International Common Disease Alliance Maps Workgroup.In addition to many local research collaborations, Benjamin serves as advisor and analyst to international genetic research consortia on psychiatric diseases.

Benjamin has worked with many different international consortia, including the International Inflammatory Bowel Disease Genetics Consortium, GiANT and the Global Lipids Genomics Consortium. He has served as a statistical advisor to analysts in other PGC working groups including addictions, autism, cross-disorder, TS/OCD and schizophrenia groups. 

Benjamin holds a B.Sc. in genetics from the University of Chicago and Virginia Commonwealth University, and a Ph.D. in human genetics from King’s College in London, UK. Neale completed his postdoctoral training in Daly’s Laboratory at MGH. 

Jennifer Cook, a Strategic Advisor at Deep Genomics and a Special Advisor to its CEO, has had a 30-year career in Biotech and Pharmaceuticals and is currently focused on providing advisory support to senior executives in the healthcare field. She serves on the Boards of Directors of Denali Therapeutics, BridgeBio Pharma, Ambys Medicines, Gyroscope Therapeutics, and Jazz Pharmaceuticals. 

Most recently, she was the Chief Executive Officer of GRAIL, a healthcare company focused on the early detection of cancer. Previously, Jennifer was at Roche Pharmaceuticals/ Genentech where she held a number of senior management positions, covering the full life-cycle of pharmaceutical product development and commercialization. Jennifer started her career in research and early development at Genentech and a venture-backed start-up company. In 2016, Jennifer was recognized for her contributions to the healthcare industry and her inspirational leadership when she was named Woman of the Year by the Healthcare Businesswomen’s Association. 

Jennifer holds a B.A. in Human Biology and M.S. in Biology from Stanford University, as well as an M.B.A. from the Haas School of Business at the University of California, Berkeley.

Matt is a Strategic Advisor to Deep Genomics. As one of the founding employees, he established and scaled the finance, legal, and HR functions, and helped build out the leadership team. He plays a central role in business development, leading biopharma transactions. He also led the company’s Series A and B financings, and helped craft and operationalize the company’s strategy.

Prior to joining Deep Genomics, he spent several years as a marine microbiologist and worked in intellectual property law. 

Matt received his J.D. and MBA from the University of Toronto with an emphasis on biotechnology, entrepreneurship, and strategy. He received his Ph.D. from the University of Cambridge, where he studied the genomes of soil bacteria using novel sequencing technologies.

Chip Baird is Chief Financial Officer at 2Seventy Bio (Nasdaq: TSVT), a commercial stage oncology cell therapy company. Prior to 2Seventy, Chip previously served as CFO for Bluebird Bio, Amicus Therapeutics, and PTC Therapeutics. Chip has more than 20 years of experience leading innovative biotech companies and also serves as a Director of Axcella Health. 

Brian O’Callaghan Is the Chief Executive Officer and board member of Deep Genomics. 

With over 30 years experience as a senior life science executive, Brian brings extensive knowledge within the biotech, big pharma and clinical research organization (CRO) sectors. Previously, he held CEO positions at ObsEva SA, Petra Pharma, Acucela, Sangart and BioPartners.  Earlier in his career, Brian held multiple senior management positions at Pfizer, Merck Serono, Novartis, Covance and NPS Pharmaceuticals. 

Brian received a Marketing Diploma from the Marketing Institute of Ireland and a Master of Business Administration (MBA) from the Henley Business School at the University of Reading.

Brendan Frey is an internationally acclaimed entrepreneur, engineer and scientist. He is Chief Innovation Officer, Founder and board member of Deep Genomics and co-founder of the Vector Institute for Artificial Intelligence. Brendan made fundamental contributions in the fields of deep learning, genomic medicine, and information technology. He co-authored over 200 papers in these areas, including over a dozen that appeared in Nature, Science and Cell and were on multiple occasions highlighted on the front covers of those magazines. His work with Geoffrey Hinton on the 'wake-sleep algorithm' helped to launch the field of deep learning (Science 1995). His work on deep learning and on factor graphs forms the foundation of thousands of products used world-wide; for example, the WiFi telecommunications standard is based on an algorithm that Brendan co-invented.

Brendan was a pioneer in developing AI systems that could accurately predict normal and pathological cell and genome biology, facilitating biomedical breakthroughs. This work led to the discovery of new biology, the founding of Deep Genomics in 2015, the first AI system for predicting pathogenic mutations and identifying therapeutic targets, and the development of new therapeutic candidates for patients with genetic disorders. 

Brendan is Professor of Engineering and Medicine at the University of Toronto and is a Fellow of the American Association for the Advancement of Science, a Fellow of the Institute of Electrical and Electronic Engineers, a Senior Fellow of the Canadian Institute for Advanced Research, and a Fellow of the Royal Society of Canada. Brendan has advised the leadership of Microsoft Research on machine learning and deep learning technology, and he was a member of its Technical Advisory Board. He has held numerous researcher and professor positions at the University of Illinois at Urbana-Champaign, Cambridge University in England, the Isaac Newton Institute for Mathematical Sciences and the University of Waterloo.

Brendan received his PhD from the University of Toronto in 1997.

Adam is a partner at True Ventures. 

Prior to True Venture, Adam worked with True portfolio company B-Stock, an online marketplace for liquidating excess inventory, and initially joined the True Ventures team as an analyst in 2010.

Adam graduated magna cum laude from the University of Florida with a bachelor’s degree in science and a master’s degree in finance. As an undergraduate, he launched and ran an independent, donation-based record label and later created “Digital Frontiers,” a course exploring how the internet and technology are changing the global business landscape, which he taught at the University of Florida. 

Maryanna Saenko is a co-founder of Future Ventures, an early-stage Venture Capital firm that invests in frontier technologies across diverse industries. She has an interest in robotics, quantum computing, biotechnology, aerospace, and the future of food. 

Previously she was at Khosla Ventures, and prior to that at DFJ, where she focused on frontier technology investments. Maryanna was also an investment partner at Airbus Ventures where she led a series of venture investments strategically aligned with Airbus’ future-of-aerospace initiatives. Before Airbus, Maryanna was a consultant at Lux Research and a research engineer at Cabot Corporation.

Maryanna graduated from Carnegie Mellon University with a B.S. in BioMedical Engineering and a B.S. and M.S. in Materials Science and Engineering.

Nessan (Ness) Bermingham, Ph.D., is Operating Partner at Khosla Ventures, where he focuses on life science companies involving nucleic acids, novel delivery systems, gene and cell therapy, novel target identification and data analytics. He is a serial biotech entrepreneur and investor, most notably having founded Intellia Therapeutics, Korro Bio and Liberate Bio. Ness was President and CEO of Intellia from its inception in 2014 until 2017, and during that time he led the company through partnering deals, financings and an IPO in 2016. Ness has held investment roles at Atlas Venture and Omega Fund Management and is Chair of F-star, Executive Chair of Korro Bio, and Executive Chair of Stylus Medicine.

Jacqueline (Jackie) Fok, Ph.D., is an Investment Vice President at SoftBank Vision Fund, focused on life sciences and health tech. She has over 10 years’ experience in the life sciences industry and was previously an investor at IP Group and a scientist in the Oncology R&D unit at AstraZeneca.

Dion Madsen has more than 25 years of experience working with innovative startups and major public companies and is the co-founder and Partner at Amplitude Ventures. 

Prior to this, he was Senior Managing Partner of the Healthcare Venture Fund at BDC Capital where the fund built two billion-dollar Canadian companies showcasing the potential of Canadian innovation. He started his venture career with RBC Capital Partners’ and moved to San Francisco in 2002 to expand RBCs platform, he was recruited to lead Unilever’s Corporate venture fund in the USA and founded and was managing director of Physic Ventures, a pioneering investor in consumer driven health.  Dion is a founding member of the C100 – a group of the leading Canadians in Silicon Valley.

Dion received his Bachelor of Commerce from the University of Saskatchewan and is a C.F.A. charterholder.